Publications by authors named "L Bhoopat"
Article Synopsis
- COVID-19 patients hospitalized face an increased risk of venous thromboembolism (VTE) even with standard anticoagulant treatment, necessitating a revised protocol for dosage adjustments.
- The study examined the effectiveness of a dynamic anticoagulation dosing guideline based on D-dimer levels, aiming to improve patient outcomes by allowing dose adjustments based on individual VTE risk.
- Results indicated that patients whose anticoagulation was adjusted had a higher in-hospital survival rate (80.2%) compared to those on fixed doses (51.3%), though there was an increased rate of bleeding events in the adjusted group.
Background: MYC/BCL2 double expression (DE) is associated with poor prognosis in patients with diffuse large B-cell lymphoma (DLBCL) receiving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP). This study aimed to determine whether the addition of DE to the National Comprehensive Cancer Network Internal Prognostic Index (NCCN-IPI) could improve the prediction of disease progression in patients with DLBCL treated with R-CHOP.
Methods: This confirmatory prognostic factor study retrospectively recruited patients with newly diagnosed DLBCL between January 1, 2014, and January 31, 2018, at Ramathibodi Hospital (RA) and Thammasat University Hospital (TU).
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive lymphoma. The standard first-line therapy for DLBCL consists of rituximab cyclophosphamide doxorubicin vincristine and prednisone (R-CHOP). About 50-70% of patients may be cured by R-CHOP.
View Article and Find Full Text PDFSickle cell disease (SCD) is associated with chronic activation of coagulation and an increased risk of venous thromboembolism. Erythrocyte sickling, the primary pathologic event in SCD, results in dramatic morphological changes in red blood cells (RBCs) because of polymerization of the abnormal hemoglobin. We used a mouse model of SCD and blood samples from sickle patients to determine if these changes affect the structure, properties, and dynamics of sickle clot formation.
View Article and Find Full Text PDFClinical and immunological characteristics of antiphospholipid syndrome in an Asian population: a retrospective study.
Asian Pac J Allergy Immunol
September 2019
Objectives: To describe the characteristics of patients with antiphospholipid syndrome (APS) in an Asian clinical practice setting.
Methods: We conducted a single-center, retrospective study of APS patients attending the rheumatology or hematology clinics, between January 2012 and December 2016.
Results: There were 450 patients suspected of having APS referred to our clinics.